Radcliffe Capital Management’s Translational Development Acquisition Corp TDAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.88M Sell
265,544
-6,396
-2% -$69.2K 0.21% 177
2026
Q2
$2.91M Sell
271,940
-233,574
-46% -$2.49M 0.22% 174
2026
Q1
$5.35M Hold
505,514
– – 0.4% 87
2025
Q4
$5.3M Buy
505,514
+1,209
+0.2% +$12.6K 0.29% 90
2025
Q3
$5.22M Buy
504,305
+329,001
+188% +$3.4M 0.32% 62
2025
Q2
$1.8M Buy
+175,304
New +$1.78M 0.14% 86

Other funds holding TDAC

Radcliffe Capital Management's TDAC Position: Q3 2026 in Review

Radcliffe Capital Management reduced its Translational Development Acquisition Corp (TDAC) stake by 2.4% in Q3 2026, selling an estimated $69.2K and leaving 265,544 shares worth $2.88M. The position accounts for 0.21% of the portfolio, ranked #177.

Radcliffe Capital Management first reported a position in TDAC in Q2 2025 and has held it in 6 quarters since. The position peaked at $5.35M in Q1 2026. 37 funds tracked by Wall St. Rank hold TDAC as of Q3 2026.

  • Radcliffe Capital Management held 265,544 shares of Translational Development Acquisition Corp worth $2.88M as of Q3 2026.
  • Radcliffe Capital Management sold 6,396 Translational Development Acquisition Corp shares in Q3 2026, an estimated $69.2K.
  • Translational Development Acquisition Corp made up 0.21% of Radcliffe Capital Management's portfolio in Q3 2026, its #177 holding.
  • Radcliffe Capital Management first reported a position in Translational Development Acquisition Corp in Q2 2025 and has held it in 6 quarters since.
  • Radcliffe Capital Management's Translational Development Acquisition Corp position peaked at $5.35M in Q1 2026.
  • 37 funds tracked by Wall St. Rank held Translational Development Acquisition Corp as of Q3 2026.

Based on Radcliffe Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.